Zobrazeno 1 - 10
of 1 565
pro vyhledávání: '"recombinant vaccinia"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pathogens, Vol 11, Iss 12, p 1505 (2022)
As demonstrated by the 2015 Zika virus outbreak in the Americas, emerging and re-emerging arboviruses are public health threats that warrant research investment for the development of effective prophylactics and therapeutics. Many arboviral diseases
Externí odkaz:
https://doaj.org/article/1ec8a532368b47bf844d1d30203231b2
Autor:
Min-Ju Kim, Ki-Back Chu, Su-Hwa Lee, Hae-Ji Kang, Keon-Woong Yoon, Md Atique Ahmed, Fu-Shi Quan
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 7, Iss 11, p 350 (2022)
Recombinant vaccinia viruses (rVV) are effective antigen delivery vectors and are researched widely as vaccine platforms against numerous diseases. Apical membrane antigen 1 (AMA1) is one of the candidate antigens for malaria vaccines but rising conc
Externí odkaz:
https://doaj.org/article/bc5e581bd02d4dfdb72a2d35ad1995d9
Publikováno v:
Vaccines, Vol 10, Iss 2, p 152 (2022)
Recombinant vaccinia viruses (rVVs) are attenuated viruses and are widely utilized as vectored vaccine platforms against numerous diseases. However, the protective efficacy of these rVV vaccines against Toxoplasma gondii and the resulting mucosal imm
Externí odkaz:
https://doaj.org/article/df23dc4a574745399070ca3299803602
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Avian Diseases, 2000 Jan 01. 44(1), 34-44.
Externí odkaz:
https://www.jstor.org/stable/1592505
Publikováno v:
Biomedicines, Vol 9, Iss 8, p 1032 (2021)
Engineered vaccinia virus (VACV) strains are used extensively as vectors for the development of novel cancer vaccines and cancer therapeutics. In this study, we describe for the first time a high-throughput approach for both fluorescent rVACV generat
Externí odkaz:
https://doaj.org/article/6f370d74c4604f37a5a8125a8e9be8bb
Autor:
Valeria Governa, Alvaro Brittoli, Valentina Mele, Maurizio Pinamonti, Luigi Terracciano, Simone Muenst, Giandomenica Iezzi, Giulio Cesare Spagnoli, Paul Zajac, Emanuele Trella
Publikováno v:
OncoImmunology, Vol 8, Iss 5 (2019)
CD40 triggering may result in antitumor effects of potentially high clinical relevance. To gain insights important for patient selection and to identify adequate targeting techniques, we investigated CD40 expression in human cancer tissues and genera
Externí odkaz:
https://doaj.org/article/0caee2dd535347c0acd37bde84686690
Autor:
Zixi Yin, Ji-Li Chen, Yongxu Lu, Beibei Wang, Leila Godfrey, Alexander J. Mentzer, Xuan Yao, Guihai Liu, Dannielle Wellington, Yiqi Zhao, Peter A.C. Wing, Wanwisa Dejnirattisa, Piyada Supasa, Chang Liu, Philip Hublitz, Ryan Beveridge, Craig Waugh, Sally-Ann Clark, Kevin Clark, Paul Sopp, Timothy Rostron, Juthathip Mongkolsapaya, Gavin R. Screaton, Graham Ogg, Katie Ewer, Andrew J. Pollard, Sarah Gilbert, Julian C. Knight, Teresa Lambe, Geoffrey L. Smith, Tao Dong, Yanchun Peng
Most existing studies characterizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses are peptide based. This does not allow evaluation of whether tested peptides are processed and presented canonically. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22e7430fe10dc4e386de114faccd8cb2
https://www.repository.cam.ac.uk/handle/1810/353626
https://www.repository.cam.ac.uk/handle/1810/353626
Autor:
Rita Calado, Joana Duarte, Pedro Borrego, José Maria Marcelino, Inês Bártolo, Francisco Martin, Inês Figueiredo, Silvia Almeida, Luís Graça, Jorge Vítor, Frederico Aires da Silva, Inês Dias, Belmira Carrapiço, Nuno Taveira
Publikováno v:
Vaccines, Vol 8, Iss 2, p 171 (2020)
Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced V
Externí odkaz:
https://doaj.org/article/5418695cb88a43149c66c422719e0bad